Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Elvira Manzano, 2 days ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Pearl Toh, 3 days ago
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.
14 Sep 2019
In type 2 diabetes patients taking sulfonylureas, hypoglycaemia duration is longer at night and is inversely correlated with the level of glycated haemoglobin (HbA1c), a new study reports.

Psychoanalytic psychotherapy shows promise for treating suicidal behaviour

11 Jun 2019

Psychoanalytic psychotherapy may effectively reduce suicidal and self-harming behaviours, with an additional benefit of improving psychosocial well-being, according to a recent study.

Researchers performed a systematic review and meta-analysis of randomized controlled trials evaluating psychoanalytic psychotherapy for suicidal behaviour, self-harm or self-injury in comparison with treatment as usual (TAU), routine psychiatric care, enhanced usual care, placebo or any other comparison, including with a different psychological therapy.

The meta-analysis included 12 trials involving 939 participants, with nine conducted on adult patients and the remaining three on adolescents. The primary endpoint was the occurrence of repeated self-harm (ie, suicide attempts and self-injuries during follow-up at intervals up to 18 months post-treatment). Secondary endpoints included depression, anxiety, psychosocial functioning and hospital admissions.

Pooled data revealed the efficacy of psychoanalytic and psychodynamic therapies in reducing the number of patients attempting suicide (odds ratio [OR], 0.469, 95 percent CI, 0.274–0.804). There was some evidence for a significantly reduced repetition of self-harm at the 6-month but not 12-month follow-up.

Moreover, psychoanalytic psychotherapy produced improvements in psychosocial functioning and reductions in a number of hospital admissions.

The intervention evaluated in all studies utilized core psychoanalytic methods to increase awareness and self-reflection; to manage, regulate or contain emotions; and to produce change through the therapeutic relationship.

The findings highlight the potential of psychoanalytic psychotherapy as an intervention that could be provided to individuals at risk of, or with a history of, suicidal or self-harming behaviour, the researchers said. Still, additional high-quality trials are needed to validate the present data and identify which specific components of the psychotherapies are effective.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Psychiatry - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Elvira Manzano, 2 days ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Pearl Toh, 3 days ago
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.
14 Sep 2019
In type 2 diabetes patients taking sulfonylureas, hypoglycaemia duration is longer at night and is inversely correlated with the level of glycated haemoglobin (HbA1c), a new study reports.